The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement



Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the development and commercialization of therapeutics, starting with eye care. Co.'s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels.

TARS SEC Filing Email Alerts Service

TARS — Key Stats (updated Fri., Mar. 14, 11:01 AM)
Company Name:  Tarsus Pharmaceuticals Inc
Website:  www.tarsusrx.com
Sector:  Biotechnology
Number of ETFs Holding TARS:  63
Total Market Value Held by ETFs:  $202.52M
Total Market Capitalization:  $1.78B
% of Market Cap. Held by ETFs:  11.36%
TARS — News
TARS — Price Chart
March 16, 2025  •  5:39 PM Eastern
Latest Market News Video


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
TARS — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree TARS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (3.78 out of 4)
71st percentile
(ranked higher than approx. 71% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite
TARS — Performance

Tarsus Pharmaceuticals Inc (TARS) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2025, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.